Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2025-12-18 00:00:00 ET · period of report 2025-12-16 · accession 0001182473-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-12-18 | 2025-12-16+ | RCUS | ROSEN TERRY J | CEO, Dir | S - Sale | $22.01 | -54.7K | 2.19M | -2% | -$1.20M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-16 | S | D | 28,947 | $21.88 | 2,220,553 | D | — | — | (F1) Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. (F2) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F4) Includes the unvested portion of the reporting person's RSU grants. (F3) Includes 236 shares purchased on November 30, 2025 through the Company's Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2025-12-17 | S | D | 25,744 | $22.16 | 2,194,809 | D | — | — | (F1) Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. (F5) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F4) Includes the unvested portion of the reporting person's RSU grants. (F3) Includes 236 shares purchased on November 30, 2025 through the Company's Employee Stock Purchase Plan. |